


The burden of antimicrobial resistance (AMR) in Kiribati

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **20 lives** have been lost each year since 1990 in Kiribati due to AMR.
- In 2021, there were an estimated **21 UI (16-26)** deaths attributable to AMR and **83 UI (65-102)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **50 to 69** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Acinetobacter baumannii* resistant to carbapenems, *Acinetobacter baumannii* resistant to fluoroquinolones and *Streptococcus pneumoniae* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Kiribati, a 10% reduction means to decrease the number of deaths associated with AMR to **75**, but currently the trend for this country could reach up to **93 UI [69-124]** AMR-associated deaths in 2030.

AMR in Kiribati

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Kiribati between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Kiribati** in 2021, there were an estimated **21 UI (16-26)** deaths attributable to AMR and **83 UI (65-102)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Kiribati has the 33rd highest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

	Overall susceptible and resistant	Associated	Attributable
Burden rank	Mycobacterium tuberculosis 84 UI (61-107) ↑	Streptococcus pneumoniae 15 UI (11-18) ↓	Acinetobacter baumannii 5 UI (4-6) ↑
	Klebsiella pneumoniae 18 UI (15-22) ↑	Klebsiella pneumoniae 13 UI (10-16) ↑	Streptococcus pneumoniae 4 UI (3-5) ↓
	Streptococcus pneumoniae 18 UI (14-21) ↓	Acinetobacter baumannii 12 UI (10-15) ↑	Klebsiella pneumoniae 4 UI (3-4) ↑
	Acinetobacter baumannii 13 UI (10-15) ↑	Escherichia coli 10 UI (8-13) ↑	Escherichia coli 2 UI (2-3) ↑
	Pseudomonas aeruginosa 13 UI (10-15) ↑	Pseudomonas aeruginosa 8 UI (6-10) ↑	Pseudomonas aeruginosa 2 UI (2-3) ↑
	Escherichia coli 12 UI (10-14) ↑	Staphylococcus aureus 7 UI (4-9) ↑	Staphylococcus aureus 2 UI (1-2) ↑
	Staphylococcus aureus 12 UI (9-14) ↑	Enterobacter spp. 2 UI (2-3) ↑	Enterobacter spp. 1 UI (1-1) ↑
	Group B Streptococcus 4 UI (3-4) ↑	Enterococcus faecalis 2 UI (2-3) ↑	Serratia spp. 0 UI (0-1) ↓
	Serratia spp. 3 UI (3-4) ↑	Serratia spp. 2 UI (2-2) ↓	Enterococcus faecalis 0 UI (0-0) ↑
	Enterococcus faecalis 3 UI (2-4) ↑	Group B Streptococcus 2 UI (1-2) ↑	Enterococcus faecium 0 UI (0-0) ↑

Annualized rate of change (1990-2021): <-3% (dark blue), -3% to -1.5% (medium blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (red), 3% to 5% (dark red), >5.0% (orange)


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

	Associated	Attributable
Burden Rank	Acinetobacter baumannii Fluoroquinolones 12 UI (10-15) ↑	Acinetobacter baumannii Carbapenems 3 UI (2-3) ↑
	Acinetobacter baumannii 4GC 12 UI (10-14) ↑	Streptococcus pneumoniae Carbapenems 3 UI (2-3) ↑
	Streptococcus pneumoniae Macrolides 12 UI (9-15) ↓	Acinetobacter baumannii Fluoroquinolones 2 UI (1-2) ↑
	Acinetobacter baumannii Carbapenems 11 UI (9-14) ↑	Pseudomonas aeruginosa Carbapenems 1 UI (1-2) ↑
	Klebsiella pneumoniae Aminoglycosides 11 UI (9-14) ↑	Klebsiella pneumoniae Aminoglycosides 1 UI (1-1) ↑
	Klebsiella pneumoniae Beta-Lactam/Lactamase Inhib. 11 UI (7-14) ↑	Klebsiella pneumoniae Carbapenems 1 UI (1-1) ↑
	Acinetobacter baumannii Anti-pseudomonal 10 UI (8-13) ↑	Staphylococcus aureus Methicillin 1 UI (0-2) ↑
	Acinetobacter baumannii Beta-Lactam/Lactamase Inhib. 10 UI (8-12) ↑	Escherichia coli 3GC 1 UI (0-1) ↑
	Acinetobacter baumannii 3GC 10 UI (7-12) ↑	Pseudomonas aeruginosa Fluoroquinolones 1 UI (0-1) ↑
	Streptococcus pneumoniae Carbapenems 9 UI (6-12) ↑	Escherichia coli Fluoroquinolones 0 UI (0-1) ↑

Annualized rate of change (1990-2021): <-3% (dark blue), -3% to -1.5% (medium blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (red), 3% to 5% (dark red), >5.0% (orange)

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) tuberculosis (84 UI (61-107)), bloodstream infections (66 UI (53-79)), lower respiratory infection (excl. COVID) (55 UI (44-66)), diarrhea (42 UI (25-60)) and infections of the skin and subcutaneous systems (15 UI (10-20)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Kiribati, people aged under 5 experienced the largest number of deaths associated with AMR in 1990 but this changed by 2021 as the largest number of deaths occurred among the 50 to 69. This indicates that prevention of infections among the under 5 has contributed to the reduction in the number of AMR associated deaths. In 2021, the number of deaths associated with AMR among the 50 to 69 was 28 UI (21-34), whereas the mortality rate per 100,000 was 860 UI (703-1,020).

Data sources for Kiribati

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Kiribati by source type

Source type	Years	Sample size	Sample size units
No other source but GBD study input	None		GBD study input

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>